Literature DB >> 11250893

Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis.

N Kobayashi1, Y Kadono, A Naito, K Matsumoto, T Yamamoto, S Tanaka, J Inoue .   

Abstract

Signals emanating from the receptor for interleukin-1 (IL-1), lipopolysaccharide (LPS) or osteoclast differentiation factor/receptor activator of NF kappa B ligand (ODF/RANKL) stimulate transcription factors AP-1 through mitogen-activated protein kinase (MAPK) activation and NF kappa B through I kappa B kinase (IKK) activation. These kinases are thought to be activated by tumor necrosis factor receptor-associated factor 6 (TRAF6). However, molecular mechanisms by which TRAF6 activates various downstream kinases remain to be elucidated. We identified functional domains of TRAF6 under physiological conditions established by appropriate expression of TRAF6 mutants in TRAF6-deficient cells. In IL-1 and LPS signaling pathways, the RING finger and first zinc finger domains are not required for NF kappa B activation but are required for full activation of MAPK. However, IL-1 and LPS signals utilize distinct regions within the zinc finger domains of TRAF6 to activate NF kappa B. Furthermore, the RING finger domain is not required for differentiation of splenocytes to multinuclear osteoclasts, but is essential for osteoclast maturation. Thus, TRAF6 plays essential roles in both the differentiation and maturation of osteoclasts by activating various kinases via its multiple domains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250893      PMCID: PMC145527          DOI: 10.1093/emboj/20.6.1271

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  43 in total

1.  Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.

Authors:  L Deng; C Wang; E Spencer; L Yang; A Braun; J You; C Slaughter; C Pickart; Z J Chen
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death.

Authors:  R H Arch; R W Gedrich; C B Thompson
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

3.  NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway.

Authors:  S C Sun; P A Ganchi; D W Ballard; W C Greene
Journal:  Science       Date:  1993-03-26       Impact factor: 47.728

4.  An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling.

Authors:  H Dadgostar; G Cheng
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

5.  Requirement for NF-kappaB in osteoclast and B-cell development.

Authors:  G Franzoso; L Carlson; L Xing; L Poljak; E W Shores; K D Brown; A Leonardi; T Tran; B F Boyce; U Siebenlist
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

6.  PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase.

Authors:  L T Duong; P T Lakkakorpi; I Nakamura; M Machwate; R M Nagy; G A Rodan
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Authors:  O Adachi; T Kawai; K Takeda; M Matsumoto; H Tsutsui; M Sakagami; K Nakanishi; S Akira
Journal:  Immunity       Date:  1998-07       Impact factor: 31.745

8.  The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily.

Authors:  L Galibert; M E Tometsko; D M Anderson; D Cosman; W C Dougall
Journal:  J Biol Chem       Date:  1998-12-18       Impact factor: 5.157

9.  ASK1 is essential for JNK/SAPK activation by TRAF2.

Authors:  H Nishitoh; M Saitoh; Y Mochida; K Takeda; H Nakano; M Rothe; K Miyazono; H Ichijo
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

10.  The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor.

Authors:  B R Wong; R Josien; S Y Lee; M Vologodskaia; R M Steinman; Y Choi
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

View more
  144 in total

1.  The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response.

Authors:  Takahito Sanada; Minsoo Kim; Hitomi Mimuro; Masato Suzuki; Michinaga Ogawa; Akiho Oyama; Hiroshi Ashida; Taira Kobayashi; Tomohiro Koyama; Shinya Nagai; Yuri Shibata; Jin Gohda; Jun-ichiro Inoue; Tsunehiro Mizushima; Chihiro Sasakawa
Journal:  Nature       Date:  2012-03-11       Impact factor: 49.962

2.  Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.

Authors:  Hasem Habelhah; Shoichi Takahashi; Ssang-Goo Cho; Takayuki Kadoya; Toshiki Watanabe; Ze'ev Ronai
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

Review 3.  Signaling to NF-kappaB: regulation by ubiquitination.

Authors:  Ingrid E Wertz; Vishva M Dixit
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

Review 4.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

Review 5.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

6.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

7.  CKIP-1 regulates macrophage proliferation by inhibiting TRAF6-mediated Akt activation.

Authors:  Luo Zhang; Yiwu Wang; Fengjun Xiao; Shaoxia Wang; Guichun Xing; Yang Li; Xiushan Yin; Kefeng Lu; Rongfei Wei; Jiao Fan; Yuhan Chen; Tao Li; Ping Xie; Lin Yuan; Lei Song; Lanzhi Ma; Lujing Ding; Fuchu He; Lingqiang Zhang
Journal:  Cell Res       Date:  2014-04-29       Impact factor: 25.617

Review 8.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

9.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

10.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.